You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK):東阿阿膠前三季度淨利潤預計增長44%至60%
格隆匯 10-11 06:27

格隆匯10月11日丨華潤醫藥(03320.HK)發佈公吿,2023年10月10日,東阿阿膠(000423.SZ)公佈其截至2023年9月30日止九個月的業績預吿。據此,其公吿截至2023年9月30日止九個月歸屬於東阿阿膠股東的淨利潤預計約人民幣7.4億元至人民幣8.2億元,比上年同期約人民幣5.13億元增長約44%至60%、扣除非經常性損益後的淨利潤預計約人民幣6.6億元至人民幣7.4億元,比上年同期約人民幣4.52億元增長約46%至64%、及基本每股收益預計約人民幣1.15元╱股至約人民幣1.27元╱股(上年同期約人民幣0.80元╱股)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account